TY - JOUR
T1 - The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma
T2 - Data From a Multicenter Cohort in Japan
AU - Komura, Kazumasa
AU - Hashimoto, Takeshi
AU - Tsujino, Takuya
AU - Muraoka, Ryu
AU - Tsutsumi, Takeshi
AU - Satake, Naoya
AU - Matsunaga, Tomohisa
AU - Yoshikawa, Yuki
AU - Takai, Tomoaki
AU - Minami, Koichiro
AU - Taniguchi, Kohei
AU - Uehara, Hirofumi
AU - Tanaka, Tomohito
AU - Hirano, Hajime
AU - Nomi, Hayahito
AU - Ibuki, Naokazu
AU - Takahara, Kiyoshi
AU - Inamoto, Teruo
AU - Ohno, Yoshio
AU - Azuma, Haruhito
N1 - Funding Information:
ACKNOWLEDGMENT This work was partially supported by the Foundation of Research Basis Development at Osaka Medical College (Japan), Grant-in-aid No. 17K16821 (Japan Society for the Promotion of Science: JSPS), the Uehara Memorial Foundation, the NOVARTIS Foundation (Japan) for the Promotion of Science, the Japan Research Foundation for Clinical Pharmacology, and Takeda Science Foundation 2018 in Japan.
Publisher Copyright:
© 2019, Society of Surgical Oncology.
PY - 2019/9/15
Y1 - 2019/9/15
N2 - Background: A myriad of studies have demonstrated the clinical association of systemic inflammatory and nutrition status (SINS) including C-reactive protein/albumin ratio (CAR), the neutrophil/lymphocyte ratio (NLR), and the platelet/hemoglobin ratio (PHR). This study aimed to investigate the predictive value of the score integrating these variables (CANLPH) in patients with renal cell carcinoma (RCC). Methods: Using cohort data from a multi-institutional study, 757 of 1109 patients were retrospectively analyzed. The optimal cutoff value for outcome prediction of continuous variables in CAR, NLR, and PHR was determined and the CANLPH score was then calculated as the sum score of 0 or 1 by the cutoff value in each ratio. Results: The median follow-up time was 76 months for the patients who survived (n = 585) and 31 months for those who died (n = 172). The Youden Index offered an optimal cutoff of 1.5 for CAR and 2.8 for NLR, and a higher value from the cutoff was assigned as a score of 1. The cutoff value of the PHR was defined as 2.1 for males and 2.3 for females. The patients were assigned a CANLPH score of 0 (47.2%), 1 (31.3%), 2 (13.1%), or 3 (8.5%). In the multivariate analysis, the CANLPH score served as an independent predictor of cancer-specific mortality in both localized and metastatic RCC. Conclusion: The score was well-correlated with clinical outcome for the RCC patients. Because this score can be concisely measured at the point of diagnosis, physicians may be encouraged to incorporate this model into the treatment for RCC.
AB - Background: A myriad of studies have demonstrated the clinical association of systemic inflammatory and nutrition status (SINS) including C-reactive protein/albumin ratio (CAR), the neutrophil/lymphocyte ratio (NLR), and the platelet/hemoglobin ratio (PHR). This study aimed to investigate the predictive value of the score integrating these variables (CANLPH) in patients with renal cell carcinoma (RCC). Methods: Using cohort data from a multi-institutional study, 757 of 1109 patients were retrospectively analyzed. The optimal cutoff value for outcome prediction of continuous variables in CAR, NLR, and PHR was determined and the CANLPH score was then calculated as the sum score of 0 or 1 by the cutoff value in each ratio. Results: The median follow-up time was 76 months for the patients who survived (n = 585) and 31 months for those who died (n = 172). The Youden Index offered an optimal cutoff of 1.5 for CAR and 2.8 for NLR, and a higher value from the cutoff was assigned as a score of 1. The cutoff value of the PHR was defined as 2.1 for males and 2.3 for females. The patients were assigned a CANLPH score of 0 (47.2%), 1 (31.3%), 2 (13.1%), or 3 (8.5%). In the multivariate analysis, the CANLPH score served as an independent predictor of cancer-specific mortality in both localized and metastatic RCC. Conclusion: The score was well-correlated with clinical outcome for the RCC patients. Because this score can be concisely measured at the point of diagnosis, physicians may be encouraged to incorporate this model into the treatment for RCC.
UR - http://www.scopus.com/inward/record.url?scp=85068013870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068013870&partnerID=8YFLogxK
U2 - 10.1245/s10434-019-07530-5
DO - 10.1245/s10434-019-07530-5
M3 - Article
C2 - 31240592
AN - SCOPUS:85068013870
VL - 26
SP - 2994
EP - 3004
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
IS - 9
ER -